A Study of EBC-129 in Advanced Solid Tumours

Inclusion Criteria

• •1. Male or female patients ≥18 years (US) or ≥21 years (Singapore) old
• •2. Body weight within ≥40 kg - ≤100 kg during Parts A and B, and ≤120 kg during all other parts of the study
• •3. Demonstrated progression of a locally advanced unresectable or metastatic solid tumour with no alternative standard-of-care therapeutic option with a proven clinical benefit, or are intolerant to these therapies
• •4. Eastern Cooperative Oncology Group (ECOG) performance status (PS) ≤ 2 for Part A and 0-1 for Parts B, C and D
• •5. Hepatic function and adequate renal function, as per protocol standard
• •6. Adequate bone marrow function as per protocol standard
• •3. Patients with a history of pneumonitis/interstitial lung disease, patients who received live vaccines within 30 days of enrolment, and patients who discontinued prior immune checkpoint inhibitors due to Grade 2 myocarditis are excluded from enrolment into pembrolizumab-containing cohorts
• •11. Has had a major surgical procedure within 4 weeks (28 days) from starting the study drug
• •12. Patients with active or chronic corneal disorders, with other active ocular conditions requiring ongoing therapy or with any clinically significant corneal disease that prevents adequate monitoring of drug-induced keratopathy
• •13. Active infection including HIV, Hepatitis B or Hepatitis C